Plasma Exeresis Plus NB-UVB Versus NB-UVB Alone for Stable Vitiligo

The goal of this quasi-experimental clinical trial is to compare the effectiveness of plasma exeresis combined with narrowband ultraviolet B (NB-UVB) phototherapy versus NB-UVB monotherapy in patients with stable non-segmental vitiligo aged 8 to 65 years. The main questions it aims to answer are: * Does plasma exeresis combined with NB-UVB produce greater repigmentation than NB-UVB alone after 24 weeks? * Is combination therapy associated with better clinical response as measured by the Vitiligo Area Scoring Index (VASI)? Researchers will compare plasma exeresis plus NB-UVB with NB-UVB alone to determine whether the combination treatment improves repigmentation. Participants will: * Receive either plasma exeresis once monthly plus NB-UVB twice weekly, or NB-UVB phototherapy alone twice weekly. * Attend follow-up visits every 4 weeks for 24 weeks. * Have their vitiligo severity assessed using the Vitiligo Area Scoring Index (VASI) at baseline and during follow-up.

Inclusion Criteria: 1. Both male and female participants. 2. Age 8-65 years. 3. Diagnosis of non-segmental stable vitiligo. 4. Vitiligo lesions located in areas accessible for treatment. Exclusion Criteria: 1. Lesions involving the face or scalp. 2. Pregnant or lactating women. 3. History of photosensitivity or skin cancer. 4. Receipt of other vitiligo treatment within the preceding 1 month.